MedTrace Logo

A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia

NCT04883996 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-05-13

No results posted yet for this study

Summary

Assess the Safety, Pharmacodynamics, and Efficacy of EXP039 Ophthalmic Solution in Participants with Myopia or Hyperopia

Conditions

  • Hyperopia
  • Myopia

Interventions

DRUG

1% EXP039

1% EXP039 (commercially available as Isopto® Carpine) contains 1% active ingredient (10 mg/mL),

OTHER

Saline control

Saline

Sponsors & Collaborators

  • Nevakar, Inc.

    collaborator INDUSTRY

  • Canyon City Eyecare

    lead OTHER

Principal Investigators

  • Milton Hom, OD FAAO · Canyon City Eyecare

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-07-31
Completion
2021-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04883996 on ClinicalTrials.gov